Insulin Market Share Report – Global Size Outlook 2022-2028
[Research Report] The insulin market is expected to grow to US$ 1,11,213.73 million by 2028 from US$ 60,183.09 million in 2022; the insulin market is estimated to grow with a CAGR of 10.8% from 2022-2028.
Analyst Perspective:
Rising prevalence of diabetes and increasing technological advancement in drug delivery devices are driving the growth of the insulin market. For instance: In May 2020, Biocon launched Semglee in vial and pre-fillled pen presentations in US. The product is offered at the lowest wholesale acquisition cost (WAC) for any long-acting Insulin Gargline on the US market. Moreover, launch of new products is the another driving factor prmoting the growth of the market. For instance: Novo Nordisk announced to launch GLP-1 injectable diabetes drug in tablet form. This oral drug will also help the patients in weight reduction and reduce cardiac risk. In 2022, North America had the largest insulin market share, followed by Europe. Further, Asia Pacific is expected to grow with a highest CAGR owing to presence of large pool of diabetic patients and increasing awareness on lifestyle disorders, increase in healthcare expenditure helps to boost the insulin market growth in the region.
Market Overview:
Insulin is a hormone that helps in lowering blood sugar levels. Insulin therapy is often an essential part of diabetes treatment. It is made by the beta cells of the pancreas and released into the blood when glucose levels rise, for example, after eating. Insulin helps the glucose to get into the body cells, which can be used for energy or stored for future use. Different types of insulin available varies in how quickly and for how long they can control blood sugar. Insulin does not come in pill form because the digestive system would break it down before it could work. Insulin therapy is exhausting; however, it is an effective way of lowering blood sugar levels.
The key factors that are driving the insulin market growth are increasing incidence of diabetes followed by rapid technological development in insulin delivery devices are the major driving factor promoting the growth of the insulin market. However, risk associated with insulin delivery devices is expected to restrict the insulin market growth during the forecast period. Europe occupies second position in the global insulin market and is expected to register robust growth rate over the forecast period. Increasing incidences of type 1 and type 2 diabetes, rising demand for insulin, and the favorable government initiatives for diabetes treatment are likely to be the major factors driving the insulin market growth of the region.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Insulin Market: Strategic Insights
Market Size Value in US$ 60,183.09 million in 2022 Market Size Value by US$ 1,11,213.73 million by 2028 Growth rate CAGR of 10.8% from 2022 to 2028 Forecast Period 2022-2028 Base Year 2022
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Insulin Market: Strategic Insights
| Market Size Value in | US$ 60,183.09 million in 2022 |
| Market Size Value by | US$ 1,11,213.73 million by 2028 |
| Growth rate | CAGR of 10.8% from 2022 to 2028 |
| Forecast Period | 2022-2028 |
| Base Year | 2022 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Market Driver:
Rapid Technological Development in Insulin Delivery Devices by Major Players Drive the Insulin Market Growth
Products with advanced insulin technology with more effective benefits are a major requirement in the treatment of diabetes. There has been a rise in advancements in diabetes treatment over the past few years. As the prevalence of diabetes is increasing worldwide, the demand for more advanced products is also boosting. The insulin market is expected to grow owing to an increase in the strategic efforts made by the industry players. The market players actively support their public and private research and academic institutes for increasing research activities.
A few of the recent developments related to rapid technological advancement in the insulin market are mentioned below:
- In May 2022, Eli Lilly and Company received USFDA approval for its Mounjar (tirzepatide) once-weekly Glucose-Dependent Insulinotropic Polypeptide (GIP) and GLP-1 Glucagon-like Peptide-1 (GLP-1) receptor agonist for the treatment of adults with type 2 diabetes. The injection is decided to be available in six doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg) as an auto-injector pen with a preattached, hidden needle.
- In Oct 2021, Adocia announced that its partner Tonghua Dongbua Pharmaceutical Co. Ltd. received the clearance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the Phase 3 clinical trial of BioChaperone Lispro, and Ultra-Rapid Insulin for the treatment of Type 1 and Type 2 diabetes.
- In October 2021, Tonghua Dongbao Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration (NMPA) for the clinical trial of its ultra-rapid-acting insulin lispro injection, BC Lispro. Currently, the drug is under phase III clinical trial initiated in China.
- In May 2021, Bigfoot Biomedical received 510(k) clearance by USFDA for its Bigfoot Unity Diabetes Management System, which features connected smartpen caps that recommend insulin doses for people using multiple daily injections (MDI) therapy.
Thus, rapid technological advancements in insulin delivery devices are boosting the growth of the global insulin market.
Segment Analysis:
Based on type, the insulin market is segmented into long-acting insulin, rapid acting insulins, short acting insulins and traditional human insulins, concentrated insulins and combination insulins, biosimilar insulins, Glucagon-like peptide-1 (GLP-1), pens and needles, and others. The long-acting insulin segment is anticipated to hold the largest market share in 2021 and however, biosimilar insulins segment is expected to register the highest CAGR of 16.0 % during the forecast period. The major driving factors for the growth of the biosimilar insulins segment are increasing applications of inbred mice in cardiovascular & immunology studies and the production of monoclonal antibodies, among others. Longer-acting insulin analogs are genetically engineered. Long-acting insulin analogs were initially developed to address the need of diabetics to maintain healthy blood sugar levels throughout the night. This insulin is slowly released into the circulation due to its acidic pH, causing it to precipitate when injected subcutaneously. Long-acting insulins are also called basal or background insulins. They keep working in the background to keep the blood sugar under control throughout the daily routine. These long-acting insulins help in controlling blood sugar for a whole day. This is similar to how the pancreas produces insulin to maintain blood sugar levels between meals. The National Health Service (NHS) has favored long-acting insulin analogs because the insulins do not have peak activity, allowing activity to be delivered consistently throughout the day.
Tresiba is a long-acting insulin used to control high blood sugar levels in adults and children aged 1 year and older with diabetes. It is not suitable for people with diabetic ketoacidosis. Tresiba contains the active ingredient insulin degludec. Tresiba is usually injected under the skin once a day at any time of the day. Long-acting insulins work continuously throughout the day to control your blood sugar between meals and overnight. It is available in 2 concentrations namely 200 units/ml and 100 units/ml. Tresiba is supplied in multidose vials or as a FlexTouch pen for single patient use. Tresiba FlexTouch is a single-use, pre-filled pen available in two different strengths, U-100 (100 units/mL) containing 300 units of insulin and U-200 (200 units/mL) containing 600 units of insulin. Tresiba must not be administered with an insulin pump or mixed with other insulins. Side effects commonly associated with Tresiba include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain.
Regional Analysis:
North America held the largest insulin market which was valued at US$ 23,946.85 million in 2022 with a CAGR of 10.5% and is expected to continue its position owing due to the significantly rising prevalence of diabetes across the countries, high prevalence of obesity, and increasing awareness regarding diabetes care in the region. In North America, the US held the largest market of 84.88% for insulin market in 2022. The US healthcare system is witnessing massive investments new product introductions. Further, the insulin market growth is attributed to increasing product development and growing government support for diabetic treatment. In addition, rising new cases of diabetes in the country is also offering a favorable growth opportunity. For instance, according to the National Diabetes Statistics Report 2020, approximately 30.3 million people in the US have diabetes representing 94% of the total population. Among the diabetic population nearly 5% of the population is diagnosed with type 1 diabetes whereas, 90-95% have type 2 diabetes. Of the more than 30 million Americans with diabetes, approximately 7.4 million rely on insulin to manage their condition. In addition, the data also revealed approximately 86 million adults aged 18 years or above were pre-diabetes and nearly 23.1 million elders above 65 years were pre-diabetes. Across the US, diabetes is the leading cause of blindness and end stage of renal diseases or renal failure among adults. Furthermore, extending network of healthcare facilities and medical tourism is likely to accelerate the insulin market growth in Mexico.
However, Asia Pacific (APAC) is the fastest-growing regional market for insulins. The market in APAC is segmented into China, India, Japan, South Korea, Australia, and the Rest of APAC. The growing global prevalence of diabetes and rising incidence rates of lifestyle-related disorders such as obesity are expected to drive market growth over the next six years. Insulin is aimed at the diabetic patient population. The rapid prevalence growth is expected to significantly impact the market growth over the forecast period. Additionally, a strong product pipeline portfolio and future commercialization of these products are expected to provide a future growth opportunity for this market.
Key Player Analysis:
Eli Lily and Company; Novo NordiskA/S; Biocon; Wockhardt; Adocia; GlaxoSmithKline plc; Sanofi; Pfizer; Merck &Co., Inc.; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Bigfoot Biomedical, Inc. amongst others. Novo NordiskA/S. and Sanofi are the top two players in the Insulin market. Novo Nordisk is a Europe based company, headquartered in Denmark. The company is focused on providing treatment for obesity, haemophilia, growth disorders and other serious chronic diseases. The company is focusing on so many therapeutic area such as Type 1 diabetes, Type 2 diabetes, Obesity, Atherosclerosis,NASH, Haemophilia and Growth disorders. The comany is operating through its subsidiaries such as Ziylo Ltd, MB2 LLC,Novo Nordisk Pharmaceuticals Limited,Novo Nordisk Pharma, S.a. among others. The company also offers treatments for diabetes, obesity, and rare blood and endocrine diseases.
Insulin Market Report Scope
Recent Developments:
Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the insulin market. A few recent key market developments are listed below:
- In Jun 2022, Sanofi and Health2Sync have signed a partnership to bring digital solutions for insulin management to Japan. Both the companies will jointly develop digitized features on insulin in Japan such as connected caps for insulin and titration alerts.
- In Jun 2022, Sanofi announced that the company would cap the monthly price of its insulin for uninsured Americans at US$ 35, down from US$ 99. The company will be commercializing the insulins such as Lantus Insulin Glargine U-100, Toujeo, Admelog, and Apidra for the uninsured at US$35 for a 30-day supply.
- In Jan 2022, Merck announced an extension to the label for metformin products in EU such as Glucophage, Glucophage XR, and Stagid for use throughout the pregnancy.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The global insulin market based on regions is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. In 2021, the North American region held the largest market share. However, the Asia Pacific region is estimated to grow at the fastest CAGR of 12.7% during the forecast period
Risks associated with insulin delivery devices are expected to restrict the insulin market growth during the forecast period.
Insulin controls the body's fat and glucose metabolism. It is a peptide hormone that is secreted by beta cells in the islets of Langerhans in the pancreas and helps in glucose metabolism regulation. It promotes glucose to be absorbed from the blood by skeletal muscle cells and fat tissues. But due to some diseases and disorders body is not able to make a sufficient amount of insulin which results in hyperglycemia due to imbalanced metabolism. In such conditions, insulin is given externally to maintain normal blood glucose levels.
The factors driving the growth of the insulin market are the increase in the incidence of diabetes and rapid technological developments in insulin delivery devices by major players.
The insulin market majorly consists of the players, such as Eli Lilly and Company; Novo Nordisk A/S; Biocon; WOCKHARDT; Adocia; GlaxoSmithKline plc.; Sanofi; Pfizer Inc.; Merck & Co., Inc.; Tonghua Dongbao Pharmaceutical Co., Ltd.; BIGFOOT BIOMEDICAL, INC.; among others.
The global insulin market based on type is segmented into long-acting insulin, rapid-acting insulin, short-acting insulin & traditional human insulin, concentrated insulin & combination insulin, biosimilar insulin, glucagonlike-peptide-1 (glp-1), pens & needles, and others. In 2021, the long-acting insulin segment held the largest share of the market. However, the biosimilar insulin segment of the insulin market is expected to register the highest CAGR of 16.0% during the forecast period.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Insulin Market – By Type
1.3.2 Global Insulin Market – By Geography
2. Insulin Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Insulin Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America– PEST Analysis
4.2.2 Europe– PEST Analysis
4.2.3 Asia Pacific– PEST Analysis
4.2.4 Middle East & Africa– PEST Analysis
4.2.5 South & Central America– PEST Analysis
4.2.6 Expert Opinion
5. Insulin Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Incidence of Diabetes
5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Major Players
5.2 Market Restraints
5.2.1 Risks Associated with Insulin Delivery Devices
5.3 Market Opportunities
5.3.1 Insufficient Competition from Biosimilars
5.4 Future Trends
5.4.1 Regeneration of Diabetic Pancreas with Advanced Transplants
5.5 Impact Analysis
6. Insulin Market– Global Analysis
6.1 Global Insulin Market Revenue Forecast and Analysis
6.1.1 Global Insulin Market, By Geography - Forecast and Analysis
6.1.2 Global Insulin Market – Market Potential Analysis, By Region
6.2 Company Analysis
6.2.1 Market Positioning of Key Players
6.2.2 Comparative Company Analysis
6.2.3 Growth Strategy Analysis
6.2.4 Performance Of Key Players
6.2.4.1 Novo Nordisk A/S
6.2.4.2 Sanofi
6.2.4.3 Eli Lily and Company
6.3 Customization Part
6.3.1 Market Share Analysis by Company
6.3.2 Market Share by Injectable GLPs
7. Insulin Market Analysis – By Type
7.2 Insulin Market Revenue Share, by Type (2021 and 2028)
7.3 Long Acting Insulin
7.3.1 Overview
7.3.2 Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Levemir
7.3.2.1.1 Overview
7.3.2.1.2 Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Lantus
7.3.2.2.1 Overview
7.3.2.2.2 Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.3 Basaglar
7.3.2.3.1 Overview
7.3.2.3.2 Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.4 Tresiba
7.3.2.4.1 Overview
7.3.2.4.2 Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Rapid Acting Insulins
7.4.1 Overview
7.4.2 Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Novolog
7.4.2.1.1 Overview
7.4.2.1.2 Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Humalog
7.4.2.2.1 Overview
7.4.2.2.2 Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.3 Admelog
7.4.2.3.1 Overview
7.4.2.3.2 Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.4 Others
7.4.2.4.1 Overview
7.4.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Short Acting Insulins and Traditional Human Insulins
7.5.1 Overview
7.5.2 Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Novolin R
7.5.2.1.1 Overview
7.5.2.1.2 Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Humulin R
7.5.2.2.1 Overview
7.5.2.2.2 Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Insuman
7.5.2.3.1 Overview
7.5.2.3.2 Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.4 Others
7.5.2.4.1 Overview
7.5.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Concentrated Insulins and Combination Insulins
7.6.1 Overview
7.6.2 Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 NovoMix
7.6.2.1.1 Overview
7.6.2.1.2 NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.2 Ryzodeg
7.6.2.2.1 Overview
7.6.2.2.2 Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.3 Xultophy
7.6.2.3.1 Overview
7.6.2.3.2 Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.4 Soliqua/Suliqua
7.6.2.4.1 Overview
7.6.2.4.2 Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Biosimilar Insulins
7.7.1 Overview
7.7.2 Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.1 Insulin Glargine
7.7.2.1.1 Overview
7.7.2.1.2 Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.2 Human Insulin
7.7.2.2.1 Overview
7.7.2.2.2 Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.8 Glucagon-like peptide-1 (GLP-1)
7.8.1 Overview
7.8.2 Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.9 Pens and Needles
7.9.1 Overview
7.9.2 Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8. Global Insulin Market – Geographic Analysis
8.1 North America: Insulin Market
8.1.1 Overview
8.1.2 North America: Insulin market - Revenue and Forecast to 2028 (US$ Million)
8.1.3 North America: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.3.1 North America: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.3.2 North America: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.3.3 North America: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.3.4 North America: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.3.5 North America: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.4 North America: Insulin Market, by Country, 2021 & 2028 (%)
8.1.4.1 US: Global Insulin market – Revenue and Forecast to 2028 (US$ Million)
8.1.4.1.1 US: Insulin market – Revenue and Forecast to 2028 (US$ Million)
8.1.4.1.2 US: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.4.1.2.1 US: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.4.1.2.2 US: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.4.1.2.3 US: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.4.1.2.4 US: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.4.1.2.5 US: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.4.2 Canada: Global Insulin market – Revenue and Forecast to 2028 (US$ Million)
8.1.4.2.1 Canada: Insulin market – Revenue and Forecast to 2028 (US$ Million)
8.1.4.2.2 Canada: Insulin Market , By Type, 2019–2028 (US$ Million)
8.1.4.2.2.1 Canada: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.4.2.2.2 Canada: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.4.2.2.3 Canada: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.4.2.2.4 Canada: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.4.2.2.5 Canada: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.4.3 Mexico: Global Insulin market – Revenue and Forecast to 2028 (US$ Million)
8.1.4.3.1 Mexico: Insulin market – Revenue and Forecast to 2028 (US$ Million)
8.1.4.3.2 Mexico: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.4.3.2.1 Mexico: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.4.3.2.2 Mexico: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.4.3.2.3 Mexico: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.4.3.2.4 Mexico: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.4.3.2.5 Mexico: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.2 Europe: Insulin Market
8.2.1 Overview
8.2.2 Europe: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
8.2.3 Europe: Insulin Market, By Type, 2019–2028 (US$ Million)
8.2.3.1 Europe: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.2.3.2 Europe: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.2.3.3 Europe: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.2.3.4 Europe: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.2.3.5 Europe: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.2.4 Europe: Insulin Market, by Country, 2021 & 2028 (%)
8.2.4.1 Germany: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4.1.1 Germany: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4.1.2 Germany: Insulin Market, By Type, 2019–2028 (US$ Million)
8.2.4.1.2.1 Germany: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.2.4.1.2.2 Germany: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.2.4.1.2.3 Germany: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.2.4.1.2.4 Germany: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.2.4.1.2.5 Germany: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.2.4.2 France: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4.2.1 France: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4.2.2 France : Insulin Market, By Type, 2019–2028 (US$ Million)
8.2.4.2.2.1 France : Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.2.4.2.2.2 France : Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.2.4.2.2.3 France : Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.2.4.2.2.4 France : Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.2.4.2.2.5 France : Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.2.4.3 UK: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4.3.1 UK: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4.3.2 UK: Insulin Market, By Type, 2019–2028 (US$ Million)
8.2.4.3.2.1 UK: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.2.4.3.2.2 UK: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.2.4.3.2.3 UK: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.2.4.3.2.4 UK: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.2.4.3.2.5 UK: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.2.4.4 Italy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4.4.1 Italy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4.4.2 Italy: Insulin Market, By Type, 2019–2028 (US$ Million)
8.2.4.4.2.1 Italy: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.2.4.4.2.2 Italy: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.2.4.4.2.3 Italy: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.2.4.4.2.4 Italy: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.2.4.4.2.5 Italy: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.2.4.5 Spain: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4.5.1 Spain: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4.5.2 Spain: Insulin Market, By Type, 2019–2028 (US$ Million)
8.2.4.5.2.1 Spain: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.2.4.5.2.2 Spain: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.2.4.5.2.3 Spain: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.2.4.5.2.4 Spain: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.2.4.5.2.5 Spain: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.2.4.6 Rest of Europe: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4.6.1 Rest of Europe: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.2.4.6.2 Rest of Europe: Insulin Market, By Type, 2019–2028 (US$ Million)
8.2.4.6.2.1 Rest of Europe: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.2.4.6.2.2 Rest of Europe: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.2.4.6.2.3 Rest of Europe: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.2.4.6.2.4 Rest of Europe: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.2.4.6.2.5 Rest of Europe: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.3 Asia Pacific: Insulin Market
8.3.1 Overview
8.3.2 Asia Pacific: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.3.3 Asia Pacific: Insulin Market, by Type, 2019–2028 (US$ Million)
8.3.3.1 Asia Pacific: Insulin Market, by Long Acting Insulin, 2019–2028 (US$ Million)
8.3.3.2 Asia Pacific: Insulin Market, by Rapid Acting Insulins, 2019–2028 (US$ Million)
8.3.3.3 Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.3.3.4 Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.3.3.5 Asia Pacific: Insulin Market, by Biosimilar Insulins, 2019–2028 (US$ Million)
8.3.4 Asia Pacific: Insulin Market, by Country, 2022 & 2028 (%)
8.3.4.1 China: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.3.4.1.1 China: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.3.4.1.2 China: Insulin Market, by Type, 2019–2028 (US$ Million)
8.3.4.1.2.1 China: Insulin Market, by Long Acting Insulin, 2019–2028 (US$ Million)
8.3.4.1.2.2 China: Insulin Market, by Rapid Acting Insulins, 2019–2028 (US$ Million)
8.3.4.1.2.3 China: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.3.4.1.2.4 China: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.3.4.1.2.5 China: Insulin Market, by Biosimilar Insulins, 2019–2028 (US$ Million)
8.3.4.2 Japan: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.3.4.2.1 Japan: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.3.4.2.2 Japan: Insulin Market, by Type, 2019–2028 (US$ Million)
8.3.4.2.2.1 Japan: Insulin Market, by Long Acting Insulin, 2019–2028 (US$ Million)
8.3.4.2.2.2 Japan: Insulin Market, by Rapid Acting Insulins, 2019–2028 (US$ Million)
8.3.4.2.2.3 Japan: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.3.4.2.2.4 Japan: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.3.4.2.2.5 Japan: Insulin Market, by Biosimilar Insulins, 2019–2028 (US$ Million)
8.3.4.3 India: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.3.4.3.1 India: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.3.4.3.2 India: Insulin Market, by Type, 2019–2028 (US$ Million)
8.3.4.3.2.1 India: Insulin Market, by Long Acting Insulin, 2019–2028 (US$ Million)
8.3.4.3.2.2 India: Insulin Market, by Rapid Acting Insulins, 2019–2028 (US$ Million)
8.3.4.3.2.3 India: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.3.4.3.2.4 India: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.3.4.3.2.5 India: Insulin Market, by Biosimilar Insulins, 2019–2028 (US$ Million)
8.3.4.4 Australia: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.3.4.4.1 Australia: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.3.4.4.2 Australia: Insulin Market, by Type, 2019–2028 (US$ Million)
8.3.4.4.2.1 Australia: Insulin Market, by Long Acting Insulin, 2019–2028 (US$ Million)
8.3.4.4.2.2 Australia: Insulin Market, by Rapid Acting Insulins, 2019–2028 (US$ Million)
8.3.4.4.2.3 Australia: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.3.4.4.2.4 Australia: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.3.4.4.2.5 Australia: Insulin Market, by Biosimilar Insulins, 2019–2028 (US$ Million)
8.3.4.5 South Korea: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.3.4.5.1 South Korea: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.3.4.5.2 South Korea: Insulin Market, by Type, 2019–2028 (US$ Million)
8.3.4.5.2.1 South Korea: Insulin Market, by Long Acting Insulin, 2019–2028 (US$ Million)
8.3.4.5.2.2 South Korea: Insulin Market, by Rapid Acting Insulins, 2019–2028 (US$ Million)
8.3.4.5.2.3 South Korea: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.3.4.5.2.4 South Korea: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.3.4.5.2.5 South Korea: Insulin Market, by Biosimilar Insulins, 2019–2028 (US$ Million)
8.3.4.6 Rest of Asia Pacific: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.3.4.6.1 Rest of Asia Pacific: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8.3.4.6.2 Rest of Asia Pacific: Insulin Market, by Type, 2019–2028 (US$ Million)
8.3.4.6.2.1 Rest of Asia Pacific: Insulin Market, by Long Acting Insulin, 2019–2028 (US$ Million)
8.3.4.6.2.2 Rest of Asia Pacific: Insulin Market, by Rapid Acting Insulins, 2019–2028 (US$ Million)
8.3.4.6.2.3 Rest of Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.3.4.6.2.4 Rest of Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.3.4.6.2.5 Rest of Asia Pacific: Insulin Market, by Biosimilar Insulins, 2019–2028 (US$ Million)
8.4 Middle East & Africa Insulin Market Revenue and Forecasts To 2028
8.4.1 Overview
8.4.2 Middle East & Africa Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.4.3 Middle East & Africa : Insulin Market, By Type, 2019–2028 (US$ Million)
8.4.3.1 Middle East & Africa : Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.4.3.2 Middle East & Africa : Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.4.3.3 Middle East & Africa : Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.4.3.4 Middle East & Africa : Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.4.3.5 Middle East & Africa : Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.4.4 Middle East & Africa Insulin Market Revenue and Forecast to 2028, by Country (%)
8.4.4.1 UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.4.4.1.1 UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.4.4.1.2 UAE: Insulin Market, By Type, 2019–2028 (US$ Million)
8.4.4.1.2.1 UAE: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.4.4.1.2.2 UAE: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.4.4.1.2.3 UAE: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.4.4.1.2.4 UAE: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.4.4.1.2.5 UAE: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.4.4.2 Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.4.4.2.1 Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.4.4.2.2 Saudi Arabia: Insulin Market, By Type, 2019–2028 (US$ Million)
8.4.4.2.2.1 Saudi Arabia: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.4.4.2.2.2 Saudi Arabia: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.4.4.2.2.3 Saudi Arabia: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.4.4.2.2.4 Saudi Arabia: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.4.4.2.2.5 Saudi Arabia: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.4.4.3 South Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.4.4.3.1 South Africa Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.4.4.3.2 South Africa: Insulin Market, By Type, 2019–2028 (US$ Million)
8.4.4.3.2.1 South Africa: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.4.4.3.2.2 South Africa: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.4.4.3.2.3 South Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.4.4.3.2.4 South Africa: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.4.4.3.2.5 South Africa: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.4.4.4 Rest of Middle East & Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.4.4.4.1 Rest of Middle East & Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.4.4.4.2 Rest of Middle East & Africa: Insulin Market, By Type, 2019–2028 (US$ Million)
8.4.4.4.2.1 Rest of Middle East & Africa: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.4.4.4.2.2 Rest of Middle East & Africa: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.4.4.4.2.3 Rest of Middle East & Africa: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.4.4.4.2.4 Rest of Middle East & Africa: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.4.4.4.2.5 Rest of Middle East & Africa: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.5 South and Central America Insulin Market Revenue and Forecasts To 2028
8.5.1 Overview
8.5.2 South and Central America: Insulin Market – Revenue and Forecast to 2028 (USD Million)
8.5.3 South and Central America: Insulin Market, By Type, 2019–2028 (US$ Million)
8.5.3.1 South and Central America: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.5.3.2 South and Central America: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.5.3.3 South and Central America: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.5.3.4 South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.5.3.5 South and Central America: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.5.4 South and Central America Insulin Market Revenue and Forecast to 2028, by Country (%)
8.5.4.1 Brazil: Insulin Market – Revenue and Forecast to 2028 (USD Million)
8.5.4.1.1 Brazil: Insulin Market – Revenue and Forecast to 2028 (USD Million)
8.5.4.1.2 Brazil: Insulin Market, By Type, 2019–2028 (US$ Million)
8.5.4.1.2.1 Brazil: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.5.4.1.2.2 Brazil: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.5.4.1.2.3 Brazil: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.5.4.1.2.4 Brazil: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.5.4.1.2.5 Brazil: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.5.4.2 Argentina: Insulin Market – Revenue and Forecast to 2028 (USD Million)
8.5.4.2.1 Argentina: Insulin Market – Revenue and Forecast to 2028 (USD Million)
8.5.4.2.2 Argentina: Insulin Market, By Type, 2019–2028 (US$ Million)
8.5.4.2.2.1 Argentina: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.5.4.2.2.2 Argentina: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.5.4.2.2.3 Argentina: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.5.4.2.2.4 Argentina: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.5.4.2.2.5 Argentina: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.5.4.3 Rest of South and Central America: Insulin Market – Revenue and Forecast to 2028 (USD Million)
8.5.4.3.1 Rest of South and Central America: Insulin Market – Revenue and Forecast to 2028 (USD Million)
8.5.4.3.2 Rest of South and Central America: Insulin Market, By Type, 2019–2028 (US$ Million)
8.5.4.3.2.1 Rest of South and Central America: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.5.4.3.2.2 Rest of South and Central America: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.5.4.3.2.3 Rest of South and Central America: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.5.4.3.2.4 Rest of South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.5.4.3.2.5 Rest of South and Central America: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
9. Impact of COVID-19 Pandemic on Global Insulin Market
9.1 North America: Impact Assessment of COVID-19 Pandemic
9.2 Europe: Impact Assessment of COVID-19 Pandemic
9.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
9.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
9.5 South and Central America: Impact Assessment of COVID-19 Pandemic
10. Insulin Market–Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Insulin Market (%)
10.3 Organic Developments
10.3.1 Overview
10.4 Inorganic Developments
10.4.1 Overview
11. Company Profile
11.1 Eli Lilly and Company
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Novo Nordisk A/S
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Biocon
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 WOCKHARDT
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Adocia
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 GlaxoSmithKline plc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Sanofi
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Pfizer Inc.
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Merck & Co., Inc.
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Tonghua Dongbao Pharmaceutical Co., Ltd.
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
11.11 BIGFOOT BIOMEDICAL, INC.
11.11.1 Key Facts
11.11.2 Business Description
11.11.3 Products and Services
11.11.4 Financial Overview
11.11.5 SWOT Analysis
11.11.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
LIST OF TABLES
Table 1. North America: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. North America: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 3. North America: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 4. North America: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 5. North America: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 6. North America: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 7. US: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 8. US: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 9. US: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 10. US: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million) 97
Table 11. US: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 12. US: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada: Insulin Market , By Type – Revenue and Forecast to 2028 (US$ Million)
Table 14. Canada: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 15. Canada: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 16. Canada: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 17. Canada: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 18. Canada: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 19. Mexico: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 20. Mexico: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 21. Mexico: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 22. Mexico: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 23. Mexico: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 24. Mexico: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 25. Europe: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 26. Europe: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 27. Europe: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 28. Europe: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 29. Europe: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 30. Europe: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 31. Germany: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 32. Germany: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 33. Germany: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 34. Germany: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 35. Germany: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 36. Germany: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 37. France: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 38. France : Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 39. France : Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 40. France : Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 41. France : Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 42. France : Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 43. UK: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 44. UK: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 45. UK: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 46. UK: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 47. UK: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 48. UK: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 49. Italy: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 50. Italy: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 51. Italy: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 52. Italy: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 53. Italy: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 54. Italy: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 55. Spain: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 56. Spain: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 57. Spain: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 58. Spain: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 59. Spain: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 60. Spain: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 61. Rest of Europe: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 62. Rest of Europe: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 63. Rest of Europe: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 64. Rest of Europe: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 65. Rest of Europe: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 66. Rest of Europe: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 67. Asia Pacific: Insulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 68. Asia Pacific: Insulin Market, by Long Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 69. Asia Pacific: Insulin Market, by Rapid Acting Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 70. Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 71. Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 72. Asia Pacific: Insulin Market, by Biosimilar Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 73. China: Insulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 74. China: Insulin Market, by Long Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 75. China: Insulin Market, by Rapid Acting Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 76. China: Insulin Market, by Short Acting Insulins and Traditional Human Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 77. China: Insulin Market, by Concentrated Insulins and Combination Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 78. China: Insulin Market, by Biosimilar Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 79. Japan: Insulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 80. Japan: Insulin Market, by Long Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 81. Japan: Insulin Market, by Rapid Acting Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 82. Japan: Insulin Market, by Short Acting Insulins and Traditional Human Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 83. Japan: Insulin Market, by Concentrated Insulins and Combination Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 84. Japan: Insulin Market, by Biosimilar Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 85. India: Insulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 86. India: Insulin Market, by Long Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 87. India: Insulin Market, by Rapid Acting Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 88. India: Insulin Market, by Short Acting Insulins and Traditional Human Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 89. India: Insulin Market, by Concentrated Insulins and Combination Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 90. India: Insulin Market, by Biosimilar Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 91. Australia: Insulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 92. Australia: Insulin Market, by Long Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 93. Australia: Insulin Market, by Rapid Acting Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 94. Australia: Insulin Market, by Short Acting Insulins and Traditional Human Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 95. Australia: Insulin Market, by Concentrated Insulins and Combination Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 96. Australia: Insulin Market, by Biosimilar Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 97. South Korea: Insulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 98. South Korea: Insulin Market, by Long Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 99. South Korea: Insulin Market, by Rapid Acting Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 100. South Korea: Insulin Market, by Short Acting Insulins and Traditional Human Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 101. South Korea: Insulin Market, by Concentrated Insulins and Combination Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 102. South Korea: Insulin Market, by Biosimilar Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 103. Rest of Asia Pacific: Insulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 104. Rest of Asia Pacific: Insulin Market, by Long Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 105. Rest of Asia Pacific: Insulin Market, by Rapid Acting Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 106. Rest of Asia Pacific: Insulin Market, by Short Acting Insulins and Traditional Human Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 107. Rest of Asia Pacific: Insulin Market, by Concentrated Insulins and Combination Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 108. Rest of Asia Pacific: Insulin Market, by Biosimilar Insulins– Revenue and Forecast to 2028 (US$ Million)
Table 109. Middle East & Africa : Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 110. Middle East & Africa : Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 111. Middle East & Africa : Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 112. Middle East & Africa : Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 113. Middle East & Africa : Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 114. Middle East & Africa : Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 115. UAE: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 116. UAE: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 117. UAE: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 118. UAE: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 119. UAE: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 120. UAE: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 121. Saudi Arabia: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 122. Saudi Arabia: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 123. Saudi Arabia: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 124. Saudi Arabia: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 125. Saudi Arabia: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 126. Saudi Arabia: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 127. South Africa: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 128. South Africa: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 129. South Africa: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 130. South Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 131. South Africa: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 132. South Africa: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 133. Rest of Middle East & Africa: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 134. Rest of Middle East & Africa: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 135. Rest of Middle East & Africa: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 136. Rest of Middle East & Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 137. Rest of Middle East & Africa: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 138. Rest of Middle East & Africa: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 139. South and Central America: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 140. South and Central America: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 141. South and Central America: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 142. South and Central America: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 143. South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 144. South and Central America: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 145. Brazil: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 146. Brazil: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 147. Brazil: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 148. Brazil: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 149. Brazil: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 150. Brazil: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 151. Argentina: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 152. Argentina: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 153. Argentina: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 154. Argentina: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 155. Argentina: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 156. Argentina: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 157. Rest of South and Central America: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 158. Rest of South and Central America: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 159. Rest of South and Central America: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 160. Rest of South and Central America: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 161. Rest of South and Central America: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 162. Rest of South and Central America: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 163. Organic Developments in the Insulin Market
Table 164. Inorganic Developments in the Insulin Market
Table 165. Glossary of Terms, Insulin Market
LIST OF FIGURES
Figure 1. Insulin Market Segmentation
Figure 2. Insulin Market Segmentation, By Region
Figure 3. Global Insulin Market Overview
Figure 4. The Long Acting Insulin Segment Held Largest Share of Type in the Insulin Market
Figure 5. Asia-Pacific Region Is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Global Insulin Market, By Geography (US$ Million)
Figure 7. Global Insulin Market- Leading Country Markets (US$ Million)
Figure 8. Global Insulin Market, Industry Landscape
Figure 9. North America PEST Analysis
Figure 10. Europe PEST Analysis
Figure 11. Asia Pacific PEST Analysis
Figure 12. Middle East & Africa PEST Analysis
Figure 13. South & Central America PEST Analysis
Figure 14. Expert Opinion
TABLE 1. PREVALENCE OF DIABETES WORLDWIDE, 2021
Figure 15. Insulin Market Impact Analysis of Drivers and Restraints
Figure 16. Global Insulin Market– Revenue Forecast and Analysis – 2020 - 2028
Figure 17. Global Insulin Market – By Geography Forecast and Analysis – 2021 - 2028
Figure 18. Global Insulin Market – Market Potential Analysis, By Region
Figure 19. Market Positioning of Key Players In Global Insulin Market
Figure 20. Global Insulin Market – Comparative Company Analysis
Figure 21. Global Insulin Market – Growth Strategy Analysis
Figure 22. Insulin Market Revenue Share, by Type (2021 and 2028)
Figure 23. Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 42. Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 43. Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 44. Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 45. Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 46. Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 47. Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 48. Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 49. North America Insulin Market, by Key Country – Revenue (2021) (US$ Million)
Figure 50. North America Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 51. North America: Insulin Market, by Country, 2021 & 2028 (%)
Figure 52. US: Insulin market – Revenue and Forecast to 2028 (US$ Million)
Figure 53. Canada: Insulin market – Revenue and Forecast to 2028 (US$ Million)
Figure 54. Mexico: Insulin market – Revenue and Forecast to 2028 (US$ Million)
Figure 55. Europe: Insulin Market, by Key Country – Revenue (2021) (US$ Million)
Figure 56. Europe Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 57. Europe: Insulin Market, by Country, 2021 & 2028 (%)
Figure 58. Germany: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 59. France: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 60. UK: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 61. Italy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 62. Spain: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 63. Rest of Europe: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 64. Asia Pacific: Insulin Market, by Key Country – Revenue (2021) (US$ Million)
Figure 65. Asia Pacific: Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 66. Asia Pacific: Insulin Market, by Country, 2022 & 2028 (%)
Figure 67. China: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 68. Japan: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 69. India: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 70. Australia: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 71. South Korea: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 72. Rest of Asia Pacific: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 73. Middle East & Africa Insulin Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 74. Middle East & Africa Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 75. Middle East & Africa Insulin Market Revenue and Forecast to 2028, by Country (%)
Figure 76. UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 77. Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 78. South Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 79. Rest of Middle East & Africa: Insulin MarketRevenue and Forecast to 2028 (US$ Million)
Figure 80. South and Central America Insulin Market Revenue Overview, By Country (2021) (US$ Mn)
Figure 81. South and Central America Insulin Market Revenue and Forecast to 2028 (USD Million)
Figure 82. South and Central America Insulin Market Revenue and Forecast to 2028, by Country (%)
Figure 83. Brazil: Insulin Market – Revenue and Forecast to 2028 (USD Million)
Figure 84. Argentina: Insulin Market – Revenue and Forecast to 2028 (USD Million)
Figure 85. Rest of South and Central America: Insulin Market – Revenue and Forecast to 2028 (USD Million)
Figure 86. Impact Of COVID-19 Pandemic in North American Country Markets
Figure 87. Impact Of COVID-19 Pandemic in Europe Country Markets
Figure 88. Impact of COVID-19 Pandemic in Asia Pacific Countries
Figure 89. Impact Of COVID-19 Pandemic in Middle East & Africa Country Markets
Figure 90. Impact of COVID-19 Pandemic in South and Central American Countries
Figure 91. Growth Strategies in the Insulin Market (%)
The List of Companies - Insulin Market
- Eli Lily and Company
- Novo NordiskA/S
- Biocon
- Wockhardt
- Adocia
- GlaxoSmitheKline plc
- Sanofi
- Pfizer
- Merck &Co., Inc.
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Bigfoot Biomedical, Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Insulin Market
Jul 2022
Infectious Disease Therapeutics Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class (Anti-viral, Anti Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography
Jul 2022
Clinic Casting and Splinting Products Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product [Casting (Casts, Tapes, Cutters, and Casting Accessories) and Splinting (Splints and Splinting Accessories)], Application (Acute Fractures or Sprains, Tendon and Ligament Injuries, and Others), Material (Plaster of Paris, Fiberglass, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jul 2022
Myopia Treatment Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (High Myopia, Degenerative Myopia, Progressive Myopia), Treatment [Low-Dose Atropine Eye Drops, Ortho-K, Contact Lenses, and Refractive Surgery (LASIK, PRK)], Age Group (Adult Myopia and Childhood Myopia), End User (Hospitals and Clinics, Specialty Clinics, and Refractive Surgery Centers), and Geography
Jul 2022
Epilepsy Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Progressive Myoclonic Epilepsy, Reflex Epilepsy, Generalized Epilepsy, and Other), Route of Administration (Oral, Parenteral, and Others), Treatment Type (First-Generation Drugs, Second-Generation Drugs, and Third-Generation Drugs), Age Group (Adults and Children), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography
Jul 2022
Vaccine Adjuvants Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others), Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant), and Geography
Jul 2022
Human Vaccine Adjuvants Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Particulate Adjuvant, Emulsion Adjuvant, Combination Adjuvant, and Others), Application (Influenza, Hepatitis, Human papilloma virus (HPV), and Others), End User (Pharmaceutical and Biotechnology Companies, CMOs and CROs, and Others), and Geography
Jul 2022
Epilepsy Drugs Market
Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment (First-Generation Anti-Epileptics, Second Generation Anti-Epileptics, Third Generation Anti-Epileptics), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Geography
Jul 2022
Specialty Hospitals Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Specialty Type (Pediatric Hospitals, Obstetrics-Gynecology Hospitals, ENT Hospitals, Oncology Hospitals, Rehabilitation Hospitals, Orthopedic Hospitals, Neurology Hospitals, Cardiology Hospitals, IVF Hospitals and Others), Service Type (Outpatient and Inpatient), Hospital Type (Public Hospitals and Private Hospitals), and Geography (North America, Europe, Asia Pacific, and Middle East & Africa)
Get Free Sample For